Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Ligand Pharmaceuticals (LGND) over the last 15 years, with Sep 2025 value amounting to $1.1 million.

  • Ligand Pharmaceuticals' Change in Accured Expenses fell 50.92% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 82.79%. This contributed to the annual value of $13.9 million for FY2024, which is 395.56% up from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Change in Accured Expenses is $1.1 million, which was up 368.55% from -$407,000 recorded in Q2 2025.
  • Ligand Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $11.3 million during Q4 2024, with a 5-year trough of -$4.8 million in Q2 2021.
  • In the last 3 years, Ligand Pharmaceuticals' Change in Accured Expenses had a median value of -$407,000 in 2025 and averaged $703,273.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Change in Accured Expenses crashed by 705.03% in 2021, and later soared by 460.57% in 2022.
  • Ligand Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at $6.4 million in 2021, then plummeted by 145.54% to -$2.9 million in 2022, then skyrocketed by 193.94% to $2.8 million in 2023, then skyrocketed by 309.36% to $11.3 million in 2024, then crashed by 50.92% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, -$407,000 for Q2 2025, and -$2.1 million during Q1 2025.